Stock Financial Ratios

CRSP / CRISPR Therapeutics AG financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)214.63
Enterprise Value ($M)-53.22
Book Value ($M)232.85
Book Value / Share19.00
Price / Book0.94
NCAV ($M)322.96
NCAV / Share26.35
Price / NCAV2.76
Income Statement (mra) ($M)
Net Income-23.20
Balance Sheet (mrq) ($M)
Cash & Equivalents253.52
Cash / Share20.68
Quick Ratio14.56
Current Ratio14.56
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.10
Return on Assets (ROA)-0.07
Return on Equity (ROE)-0.10
Identifiers and Descriptors
Central Index Key (CIK)1674416
Industry Groups
Share Statistics
Common Shares Outstanding (M)41.02
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Retained Earnings Per Share-10.25
Property Plant And Equipment Net Per Share1.60
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Other Non Current Per Share0.05
Current Portion Of Long Term Debt Per Share0.00
Cash Per Share20.68
Inventory Raw Materials Per Share0.00
Equity Per Share14.60
Assets Other Current Per Share0.00
Accounts Receivable Per Share0.26
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share20.68
Assets Per Share23.03
Additional Paid In Capital Per Share24.74
Accumulated Depreciation And Depletion Per Share0.25
Liabilities Current Per Share0.99
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Gross Per Share1.85
Long Term Debt Per Share0.00
Property Plant And Equipment Per Share1.60
Treasury Stock Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Liabilities Per Share8.43
Liabilities And Stock Equity Per Share23.03
Intangibles Per Share0.00
Assets Current Per Share21.10
Goodwill Per Share0.00
Liabilities Other Non Current Per Share0.01

Related News Stories

Sangamo's Powerful Pipeline Drives Significant Upside

2017-11-17 seekingalpha
While there has been a high level of excitement over the past few years with regard to CRISPR gene editing possibilities, some of the previously leading methods for effective genome manipulation and gene therapy have been lost in the mix. Sangamo Therapeutics (SGMO) has a strong proprietary product in their Zinc Finger Nuclease [ZFN] technology for genome modulation. They have recently generated significant buzz surrounding their widely successful quarter, and have laid a strong foundation moving forward. (52-0)

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials

2017-11-10 seekingalpha
CRSP's update on their pipeline is encouraging - IND on track for 2017, first company in the CRISPR-Cas9 clinical space. (25-0)

Calyxt Jumping Into A Crowded Space

2017-10-31 seekingalpha
Calyxt is using the excitement regarding cutting edge technologies in the genome editing space to support its product pipeline. (49-0)

Vertex Pharmaceuticals (VRTX) Q3 2017 Results - Earnings Call Transcript

2017-10-26 seekingalpha
Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Third Quarter 2017 Financial Results Conference Call. Participants are now in a listen-only mode. And later, we will open the lines for question. This call is recorded. A replay will be available later tonight on our website. (11-0)

Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack

2017-10-23 seekingalpha
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-1)

CUSIP: H17182108